Decreased ABAT gene expression, including due to hypermethylation, was shown to be associated with aggressive tumor behavior, resistance to adjuvant chemotherapy, and poor prognosis in some primary non-CNS cancers, such as breast, liver and adrenocortical carcinomas (66–68). This evidence concerns the gene ABAT and neoplasm.